fezolinetant
Selected indexed studies
- Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. (J Clin Endocrinol Metab, 2023) [PMID:36734148]
- Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. (Lancet, 2023) [PMID:36924778]
- Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial. (Obstet Gynecol, 2023) [PMID:36897180]
_Worker-drafted node — pending editorial review._
Connections
fezolinetant is a side effect of
Sources
- Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. (2023) pubmed
- Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. (2023) pubmed
- Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis. (2025) pubmed
- Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial. (2023) pubmed
- Fezolinetant in the treatment of vasomotor symptoms associated with menopause. (2021) pubmed
- Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause. (2024) pubmed
- Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. (2024) pubmed
- Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms. (2023) pubmed
- Fezolinetant. (2012) pubmed
- Fezolinetant: First Approval. (2023) pubmed